Ph.D., Pharmacology, National Taiwan University;
Instructor in Pediatrics, Harvard Medical School;
Research Associate in Immunology, Boston Children's Hospital
The goal of our laboratory is to determine how the newly defined innate immune cell subsets (ILC and NKT) regulate the development of asthma, autoimmune diseases, and microbial infections. Innate lymphoid cells (ILC), a type of non-T non-B lymphoid cells, represent an emerging family of cell types that seem to have crucial roles in the development of autoimmune diseases and in regulating the innate immunity towards pathogenic and nonpathogenic microorganisms. Another innate immune cell subset, Natural Killer T cells (NKT), which express both NK and T cell markers, are activated by glycolipid antigens, particularly from certain bacteria. They have been found to modulate the process of immune response and participate in the development of several diseases. Despite the importance of these innate immune cell subsets in immunology and in human health, the mechanisms on how these cells activate and regulate disease processes are not well understood. Our research projects take advantage of our mouse models for asthma, as well as being well versed in characterizing ILCs in the lungs. We are interested in studying the mechanistic interactions between respiratory pathogens and lung functional disorders, as well as the mechanisms of how ILCs interplay with other innate or adaptive immune cells in the pathogenesis of asthma and infectious diseases. We are particularly interested in the development of therapeutic agents targeting the innate immune cell subsets in asthma, autoimmune and infectious diseases.
The modulation of pulmonary group 2 innate lymphoid cell function in asthma: from inflammatory mediators to environmental and metabolic factorsExperimental & Molecular Medicine, Sep 11, 2023
Neutrophil extracellular trap production and CCL4L2 expression influence corticosteroid response in asthmaScience Translational Medicine, Jun 07, 2023